Financial Snapshot

Revenue
$45.62M
TTM
Gross Margin
92.64%
TTM
Net Earnings
-$94.58M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
495.47%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$228.1M
Q3 2024
Cash
Q3 2024
P/E
-1.991
Nov 29, 2024 EST
Free Cash Flow
-$140.9M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $100.4M $91.50M $54.52M $248.1M $44.30M $54.58M
YoY Change 9.72% 67.81% -78.03% 460.15% -18.84%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $100.4M $91.50M $54.52M $248.1M $44.30M $54.58M
Cost Of Revenue $2.099M $1.726M $2.517M $5.396M $2.978M $885.0K
Gross Profit $98.29M $89.77M $52.01M $242.7M $41.32M $53.69M
Gross Profit Margin 97.91% 98.11% 95.38% 97.83% 93.28% 98.38%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $69.41M $79.45M $93.51M $90.90M $81.65M $53.63M
YoY Change -12.63% -15.03% 2.87% 11.33% 52.24%
% of Gross Profit 70.62% 88.5% 179.8% 37.45% 197.6% 99.88%
Research & Development $230.8M $248.7M $261.9M $296.5M $297.6M $200.5M
YoY Change -7.23% -5.04% -11.65% -0.4% 48.46%
% of Gross Profit 234.78% 277.08% 503.68% 122.14% 720.38% 373.39%
Depreciation & Amortization $10.29M $11.53M $16.35M $13.19M $12.59M $13.35M
YoY Change -10.82% -29.46% 23.98% 4.77% -5.68%
% of Gross Profit 10.46% 12.85% 31.44% 5.43% 30.46% 24.85%
Operating Expenses $300.2M $328.2M $355.4M $387.4M $379.3M $257.1M
YoY Change -8.54% -7.67% -8.24% 2.13% 47.52%
Operating Profit -$237.6M -$263.1M -$313.9M -$138.2M -$340.7M -$203.4M
YoY Change -9.7% -16.18% 127.22% -59.45% 67.49%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense $12.41M $2.932M $88.00K $0.00 $0.00 -$15.49M
YoY Change 323.36% 3231.82% -100.0%
% of Operating Profit
Other Income/Expense, Net $7.625M $6.055M $21.65M $18.06M $20.13M $19.16M
YoY Change 25.93% -72.03% 19.89% -10.29% 5.03%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income -$217.6M -$254.2M -$292.2M -$120.1M -$320.6M -$199.7M
YoY Change -14.39% -13.02% 143.28% -62.53% 60.5%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$217.6M -$254.2M -$292.2M -$120.1M -$320.6M -$199.7M
YoY Change -14.39% -13.02% 143.27% -62.53% 60.5%
Net Earnings / Revenue -216.73% -277.77% -535.93% -48.41% -723.75% -365.98%
Basic Earnings Per Share -$4.42 -$7.13 -$12.44 -$5.14 -$13.72
Diluted Earnings Per Share -$4.42 -$7.13 -$12.44 -$5.14 -$13.72 -$8.548M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $217.0M $266.3M $265.1M
YoY Change -18.51% 0.46%
Cash & Equivalents $74.96M $71.03M $130.4M
Short-Term Investments $142.0M $195.2M $134.6M
Other Short-Term Assets $7.365M $13.65M $9.512M $14.41M $13.42M
YoY Change -46.05% 43.52% -34.0% 7.43%
Inventory
Prepaid Expenses
Receivables $13.41M $20.96M $17.00M $10.69M $7.426M
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $237.8M $300.9M $291.6M $25.10M $20.84M
YoY Change -20.98% 3.2% 1061.42% 20.45%
Property, Plant & Equipment $278.1M $296.6M $310.4M $260.5M $257.5M
YoY Change -6.24% -4.45% 19.18% 1.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.816M $1.414M $97.12M
YoY Change 240.59% -98.54%
Other Assets $38.14M $38.39M $38.59M $8.263M $14.05M
YoY Change -0.65% -0.52% 367.05% -41.2%
Total Long-Term Assets $327.7M $355.8M $468.1M $287.5M $294.1M
YoY Change -7.9% -24.0% 62.81% -2.24%
Total Assets $565.4M $656.7M $759.7M $312.6M $314.9M
YoY Change
Accounts Payable $6.028M $7.208M $6.024M $7.152M $20.39M
YoY Change -16.37% 19.65% -15.77% -64.92%
Accrued Expenses $38.35M $65.84M $65.18M $58.66M $64.15M
YoY Change -41.76% 1.02% 11.11% -8.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $59.78M $79.79M $98.39M $75.87M $103.4M
YoY Change -25.08% -18.9% 29.68% -26.62%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $250.3M $266.4M $301.5M $162.1M $167.9M
YoY Change -6.03% -11.63% 85.95% -3.42%
Total Long-Term Liabilities $250.3M $266.4M $301.5M $162.1M $167.9M
YoY Change -6.03% -11.63% 85.95% -3.42%
Total Liabilities $310.1M $346.2M $399.9M $238.0M $271.3M
YoY Change -10.42% -13.42% 68.01% -12.26%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 49.28M shares 35.64M shares 23.50M shares 23.37M shares 23.37M shares
Diluted Shares Outstanding 49.28M shares 35.64M shares 23.50M shares 23.37M shares 23.37M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $188.3 Million

About 2seventy bio, Inc.

2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 274 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.

Industry: Pharmaceutical Preparations Peers: Allakos Inc. Stoke Therapeutics, Inc. Entrada Therapeutics, Inc. G1 Therapeutics, Inc. Immunovant, Inc. Imago BioSciences, Inc. Kinnate Biopharma Inc. PMV Pharmaceuticals, Inc.